Cargando…

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests

INTRODUCTION: We aimed to define prodromal Alzheimer's disease (AD) and AD dementia using normative neuropsychological data in a large population‐based cohort of adults with Down syndrome (DS). METHODS: Cross‐sectional study. DS participants were classified into asymptomatic, prodromal AD and A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benejam, Bessy, Videla, Laura, Vilaplana, Eduard, Barroeta, Isabel, Carmona‐Iragui, Maria, Altuna, Miren, Valldeneu, Silvia, Fernandez, Susana, Giménez, Sandra, Iulita, Florencia, Garzón, Diana, Bejanin, Alexandre, Bartrés‐Faz, David, Videla, Sebastià, Alcolea, Daniel, Blesa, Rafael, Lleó, Alberto, Fortea, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322242/ https://www.ncbi.nlm.nih.gov/pubmed/32613076 http://dx.doi.org/10.1002/dad2.12047

Ejemplares similares

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
por: Benejam, Bessy, et al.
Publicado: (2022)

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
por: Videla, Laura, et al.
Publicado: (2022)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Evaluation of biochemical and hematological parameters in adults with Down syndrome
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
por: Iulita, Maria Florencia, et al.
Publicado: (2022)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
por: Belbin, Olivia, et al.
Publicado: (2020)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
por: Pegueroles, Jordi, et al.
Publicado: (2020)

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
por: Bejanin, Alexandre, et al.
Publicado: (2021)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study
por: Pegueroles, Jordi, et al.
Publicado: (2018)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2021)

Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2023)

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer’s Disease
por: Giménez, Sandra, et al.
Publicado: (2022)

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease
por: Jimenez, Amanda, et al.
Publicado: (2017)

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders
por: Alcolea, Daniel, et al.
Publicado: (2019)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders
por: Delaby, C., et al.
Publicado: (2020)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
por: Altuna, Miren, et al.
Publicado: (2022)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
por: Moreau, Manon, et al.
Publicado: (2022)

AMYQ: An index to standardize quantitative amyloid load across PET tracers
por: Pegueroles, Jordi, et al.
Publicado: (2021)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2019)

APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
por: Sampedro, Frederic, et al.
Publicado: (2015)

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia
por: Illán‐Gala, Ignacio, et al.
Publicado: (2019)

Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity
por: Altuna, Miren, et al.
Publicado: (2021)

Neuropsychological assessment in preclinical and prodromal Alzheimer disease: a global perspective
por: Watermeyer, Tamlyn, et al.
Publicado: (2019)

Combination Therapy for Neuropathic Pain: A Review of Recent Evidence
por: Serrano Afonso, Ancor, et al.
Publicado: (2021)

CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease
por: Paajanen, T., et al.
Publicado: (2013)

Neuropsychological Impairment in Prodromal, First-Episode, and Chronic Psychosis: Assessing RBANS Performance
por: Zhang, TianHong, et al.
Publicado: (2015)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
por: de Sola, Susana, et al.
Publicado: (2015)

Neuropsychological deficits in patients with cognitive complaints after COVID‐19
por: García‐Sánchez, Carmen, et al.
Publicado: (2022)

Sleep Disorders in Adults with Down Syndrome
por: Giménez, Sandra, et al.
Publicado: (2021)

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
por: Perea, Juan R., et al.
Publicado: (2018)

Maternidad : Mito y realidad
por: Videla, Mirta
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_8sfp7tg0usa7eljlds6gpgihli